NASA Solicits Ideas for International Space Station Research

WASHINGTON -- NASA wants to know how you can improve the International Space Station as a technology test bed.

NASA's International Space Station National Laboratory and Technology Demonstration offices are asking for proposals on how the space station may be used to develop advanced or improved exploration technologies. NASA also is seeking proposals about how new approaches, technologies and capabilities could improve the unique laboratory environment of the orbiting outpost.

The NASA Research Announcement, "Soliciting Proposals for Exploration Technology Demonstration and National Lab Utilization Enhancements," may be viewed at: http://go.nasa.gov/Uqkccz

The annoucement will provide successful proposers access to the space station's microgravity environment, crew support and robotic servicing. It closes Sept. 30.

"The space station is a world-class facility and critical to NASA's plan to extend humanity's presence beyond low-Earth orbit," said Andrew Clem of the Technology Demonstration Office in the International Space Station Program at NASA's Johnson Space Center in Houston. "This is an opportunity for researchers, inventors and designers to demonstrate a technology needed for future human spaceflights or to improve an existing space station capability."

NASA will review submissions throughout the year as they are received. The agency will cover launch and integration costs for selected proposals. Successful submissions also may be eligible for limited additional funding.

Proposed technologies should help advance exploration and research capabilities aboard the space station. Concepts must fit within existing NASA standards for mass and volume to meet requirements for current launch vehicles. Suggested areas include in-space propulsion; space power and energy storage; components of highly reliable, closed-loop, human health, life support and habitation systems; thermal systems; robotics, telerobotics, and autonomous systems; and human exploration destination systems.

Proposals for new exploration technologies could include strategies to reduce mass, maintenance and power requirements, while also increasing efficiency, reliability and safety. The idea could be a new technology or a new, improved use of existing space hardware. Proposals also may have the potential to yield benefits for humanity, such as testing a new material or stimulating economic growth.

Alternately, proposers could address improvements to the existing capabilities of the U.S. National Laboratory, such as new uses for existing experiment tools and infrastructure aboard the orbiting outpost, or potential efficiencies like advances in data communications. Other possibilities include ground equipment for space studies, in-orbit analytical tools, three-dimensional cell and tissue culture hardware, or improvements or new uses for existing station research resources.

The enhancements sought in this announcement will further efforts by the Center for the Advancement of Science in Space to promote research aboard the station's U.S. National Laboratory.

Go here to see the original:

NASA Solicits Ideas for International Space Station Research

NASA's New Comsat: TDRS-K Spacecraft in Photos

TDRS-K Spacecraft in Hangar

The TDRS-K spacecraft stands inside a processing hangar in Titusville, Fla., awaiting packaging for launch into orbit 22,300 miles above Earth.

An artist concept of the TDRS-K spacecraft in orbit with its assortment of antennas and a pair of solar arrays to provide electricity.

Technicians inspect the payload fairing placed over NASA's Tracking and Data Relay Satellite, TDRS-K, inside the Astrotech payload processing facility in Titusville, Fla., near NASAs Kennedy Space Center.

Technicians move the second half of the payload fairing into place over NASA's Tracking and Data Relay Satellite, TDRS-K, inside the Astrotech payload processing facility in Titusville, Fla., near NASAs Kennedy Space Center. This image was released Jan. 16, 2013.

NASA's Tracking and Data Relay Satellite, TDRS-K, stands inside one half of the payload fairing as the spacecraft is encapsulated inside the Astrotech payload processing facility in Titusville, Fla., near NASAs Kennedy Space Center. This image was released Jan. 16, 2013.

NASA's Tracking and Data Relay Satellite, TDRS-K, stands inside one half of the payload fairing as the spacecraft is encapsulated inside the Astrotech payload processing facility in Titusville, Fla., near NASAs Kennedy Space Center. This image was released Jan. 16, 2013.

Technicians move one half of the payload fairing into place over NASA's Tracking and Data Relay Satellite, TDRS-K, inside the Astrotech payload processing facility in Titusville, Fla., near NASAs Kennedy Space Center.

Inside the Astrotech payload processing facility in Titusville, Fla. near NASAs Kennedy Space Center, the Tracking and Data Relay Satellite, TDRS-K, is being checked out prior to being encapsulated in the nose faring. This image was released Jan. 16, 2013.

In the Astrotech payload processing facility in Titusville, Fla. near NASAs Kennedy Space Center, the payload faring for the Tracking and Data Relay Satellite, TDRS-K, has been checked out and awaits the arrival of the TDRS-K. This image was released Jan. 16, 2013.

Read the original here:

NASA's New Comsat: TDRS-K Spacecraft in Photos

Innovative uses of nanotechnology in food and agriculture

Public release date: 28-Jan-2013 [ | E-mail | Share ]

Contact: Vicki Cohn vcohn@liebertpub.com 914-740-2100 x2156 Mary Ann Liebert, Inc./Genetic Engineering News

New Rochelle, NY, January 28, 2013The U.S. Department of Agriculture (USDA) invests nearly $10 million a year to support about 250 nanoscale science and engineering projects that could lead to revolutionary advances in agriculture and food systems. Examples of current projects in development are presented in a Special Research Section published in Industrial Biotechnology, a peer-reviewed journal from Mary Ann Liebert Inc., publishers. The articles are available on the Industrial Biotechnology website.

In their introductory article, "Overview: Nanoscale Science and Engineering for Agriculture and Food Systems," Co-Guest Editors Norman Scott, PhD, Professor, Cornell University (Ithaca, NY) and Hongda Chen, PhD, National Program Leader, National Institute of Food and Agriculture, USDA (Washington, DC), describe the promising early advances nanotechnology is enabling all along the food supply chain, from production through consumption, and especially in the area of food safety.

This special issue of IB includes the review article "Bioactivity and Biomodification of Ag, ZnO, and CuO Nanoparticles with Relevance to Plant Performance in Agriculture" by Anne Anderson and coauthors, Utah State University, Logan, in which they discuss the environmental factors that affect the biological activity and potential agricultural utility of nanoparticle. In the original research article "Effect of Silver Nanoparticles on Soil Denitrification Kinetics" Allison Rick VandeVoort and Yuji Arai, Clemson University (South Carolina), describe the effects of three different silver nanoparticles on native bacteria-mediated soil denitrification.

The short communication "Soft Lithography-Based Fabrication of Biopolymer Microparticles for Nutrient Microencapsulation" by Natalia Higuita-Castro, et al., The Ohio State University and Abbott Nutrition Products Division, Columbus, OH, describes a high-throughput microfabrication method to encapsulate nutrients that can enhance food nutritional value and appearance. Dan Luo and colleagues, Cornell University, Ithaca, NY, present a promising microfluidic-based scale-up method for cell-free protein production in the methods article "Cell-Free Protein Expression from DNA-Based Hydrogel (P-Gel) Droplets for Scale-Up Production."

"The rapid expansion in nanoscale science and technology in our community with new insights and methods in biomolecular and cellular processing will spur industrial biotechnology innovation in a number of important sectors," says Larry Walker, PhD, Co-Editor-in-Chief and Professor, Biological & Environmental Engineering, Cornell University, Ithaca, NY.

###

About the Journal

Industrial Biotechnology, led by Co-Editors-in-Chief Larry Walker, PhD, and Glenn Nedwin, PhD, MBA, is an authoritative journal focused on biobased industrial and environmental products and processes, published bimonthly in print and online. The Journal reports on the science, business, and policy developments of the emerging global bioeconomy, including biobased production of energy and fuels, chemicals, materials, and consumer goods. The articles published include critically reviewed original research in all related sciences (biology, biochemistry, chemical and process engineering, agriculture), in addition to expert commentary on current policy, funding, markets, business, legal issues, and science trends. Industrial Biotechnology offers the premier forum bridging basic research and R&D with later-stage commercialization for sustainable biobased industrial and environmental applications.

Originally posted here:

Innovative uses of nanotechnology in food and agriculture

Chiefs lose 4-3 to Medicine Hat

by Spokane Chiefs

KREM.com

Posted on January 27, 2013 at 12:24 AM

Medicine Hat scored the go-ahead goal at 7:54 in the third and held off a furious rally from Spokane as the Tigers defeated the Chiefs 4-3 in front of 7,910 fans at the Spokane Arena Saturday night. Todd Fiddler scored two goals and added one assist as the Chiefs fell to 16-9-0-0 at home and 30-18-2-0 overall.

The first period belonged to the net minders as the two teams combined for 30 shots but just one goal. Fiddler, who now leads the W.H.L. with 35 goals, provided that score at the 17:15 mark as he beat Cam Lanigan off a great feed from Mike Aviani.

Medicine Hat piled up 16 shots for the period but couldn't light the lamp as Garret Hughson excelled between the pipes in the early going.

The Tigers flipped the script in the second, scoring the period's only two goals despite being outshot 20-7 by the Chiefs. Boston Leier scored Medicine Hat's first goal at 3:49 and Hunter Shinkaruk gave the Tigers a 2-1 advantage as he snuck the puck past Hughson five-hole at the 8:30 mark.

The final stanza was a back-and-forth affair with the two teams trading goals at a breakneck pace to start the period. Spokane struck first just 8-seconds into the period as Todd Fiddler raced down the ice after the Chiefs won the faceoff and fired a shot past Lanigan glove-side for the score.

Fiddlers goal, assisted on by Brenden Kichton and Dylan Walchuk, tied the mark set by Tony Horacek in 1988 for the fastest goal to open a period in Chiefs history.

Medicine Hat responded with a score at 2:29 from Miles Koules only to see Blake Gal notch the equalizer 11-seconds later on assists from Fiddler and Walchuk. The Tigers Curtis Valk scored the game-winning goal on a power play at 7:54 and Lanigan kept Spokane off the board in a frenetic final minute of the game.

See original here:

Chiefs lose 4-3 to Medicine Hat

Tulane University Study Published In The American Journal of Medicine Finds Nutritional Management With Metanx® …

NEW ORLEANS, Jan. 28, 2013 /PRNewswire/ --Pamlab L.L.C., developer and marketer of Metanx, announced today that a multicenter study, done in collaboration with Tulane University, was published in The American Journal of Medicine. The study suggests that nutritional management of diabetic peripheral neuropathy (DPN) with L-methylfolate, methylcobalamin, and pyridoxal 5'-phosphate, a prescription medical food dispensed by prescription and commercially known as Metanx, improves total symptoms and health-related quality of life. The study, conducted by Vivian A. Fonseca, M.D. Tullis-Tulane Alumni Chair in Diabetes, Professor of Medicine and Chief, Section of Endocrinology at Tulane University School of Medicine, found significant improvement in both these areas after 24 weeks.

Type 2 Diabetes patients with symptomatic neuropathy often experience total symptoms including numbness, tingling and burning pain in the feet and/or hands. It is estimated that diabetic neuropathy affects 60-70 percent of the 26 million people in the U.S. with Type 2 diabetes. Nutritional management with Metanx is believed to regulate the metabolic processes responsible for maintaining blood flow in the vessels that carry important nutrients and oxygen to the peripheral nerves.

Two hundred fourteen patients with Type 2 DPN were enrolled in the multicenter, double blind, placebo-controlled study and were randomized 1:1 to receive either Metanx or identical placebo for 6 months. The Neuropathy Disability Score with Metanx demonstrated greater improvement than placebo at 16 weeks, as was the Neuropathy Total Symptom Score-6 (NTSS-6), which showed greater improvement at 16 and 24 weeks in the Metanx group than the placebo group. Significant improvement in quality of life was also observed with Metanx in the Short Form-36 (SF-36) Mental Component subscale after 24 weeks compared to placebo.

There were no differences in total adverse events in the Metanx group compared to the placebo group. Adverse events were infrequent, with each event that was reported occurring in <2% of all subjects.

Dr. Fonseca commented on the study, "This study demonstrated that significant improvements with Metanx were observed in measures of neuropathic symptoms and health-related quality of life, factors which may have a greater impact on patients' well being. This verifies that Metanx could be a useful tool in managing patients with symptomatic diabetic neuropathy. Unlike current therapies on the market, Metanx has a unique mechanism of action that may be related to the pathophysiology of Diabetic Peripheral Neuropathy. I am delighted that Tulane University was able to work with Metanx (Pamlab, L.L.C.), a New Orleans area health care company, to conduct research that improves the lives of patients with diabetes."

The study can be found in The American Journal of Medicine and online here: http://www.ncbi.nlm.nih.gov/pubmed/23218892

About Diabetic NeuropathyDiabetic neuropathy, or nerve damage caused by diabetes, is a chronic, progressive condition characterized by tingling, burning pain and numbness in the feet and/or hands. Numbness in the feet is the most common symptom associated with diabetic neuropathy and is the most frequent cause of ulceration and non-traumatic amputation. Additionally, burning pain occurs in 10 to 25 percent of DPN patients. Current therapies mask the painful symptoms of DPN but do not address the natural history of the disease, a challenge currently facing healthcare providers.

About Medical Foods and MetanxMedical foods are specially formulated to manage a specific disease or condition for which medical evaluation, based on recognized scientific principles, has established distinct nutritional requirements. All components of a medical food must have GRAS status (Generally Recognized as Safe) or be an approved food additive.

Metanx is a medical food dispensed by prescription and indicated for the distinct nutritional requirements of patients with endothelial dysfunction who present with loss of protective sensation and neuropathic pain associated with diabetic neuropathy. Metanx offers a nutritional benefit by improving endothelial function and maintaining blood flow in the vessels that carry important nutrients and oxygen to the peripheral nerves.

About Pamlab, L.L.C.Pamlab, L.L.C., founded in 1957, is a fully integrated pharmaceutical company specializing in medical foods indicated for the nutritional support of specific disease states including diabetic neuropathy, depression and mild cognitive impairment.

See the rest here:

Tulane University Study Published In The American Journal of Medicine Finds Nutritional Management With Metanx® ...

Did This 15-Year-Old Kid Just Change the Course of Medicine?

When you were 15, chances are, revolutionizing medicine wasn't among your after-school activities. But for 15-year-old Jack Andraka, it's par for the course. The high school sophomore recently developed a revolutionary new test for early-stage pancreatic cancer. This, before he could legally drive a car.

This past December, Andraka won Intels prestigious Gordon E. Moore Award along with other top honors at the corporations annual Science and Engineering Fair, the worlds largest high school research and science competition. Jack Andraka created a simple dip-stick sensor to test for levels of mesothelin, which is a biomarker for early-stage pancreatic cancer thats found in blood and urine. The method is similar to diabetic testing strips, utilizing just a pinprick of blood and costing all of three cents to make.

Jack Andraka was moved by the frustrating realities of pancreatic cancer, a particularly lethal form of the disease, after a family friend passed away from it. But it wasn't until he was sitting in class sometime later that a solution struck him. Andraka tells TakePart, I came up with the idea when I was in science class. I was supposed to be paying attention, but then I had this epiphany.

Whats so revolutionary about Andraka's epiphany, aside from possibly being the most inexpensive medical test ever devised, is that current methods for pancreatic cancer detection are woefully ineffectivefor the most part, they're unable to uncover the presence of the disease until its in its final stages, long after it could respond to treatment. That's why the American Cancer Society reports that on average, the one-year survival rate for a patient is just 20 percent, and the five-year rate is a dismal four percent.

However, Andrakas prize-winning invention means patients could be armed with a simple method to detect the disease in its earliest incarnations, before it becomes invasive and when it still has a chance to respond to medical care. Early detection could bump up survival rates dramatically, edging them "close to 100 percent" according to Andraka. And for a disease that takes the lives of approximately 40,000 people each year, that's saying a lot.

But this is about more than pancreatic cancer. Andraka explains his strips can be altered to detect biomarkers for other conditions as well. Whats so cool about that is its applicability to other diseasesfor example other forms of cancer, tuberculosis, HIV, environmental contaminants like E Coli, salmonella, he says. All for three cents for a test that takes five minutes to run.

He has big plans to turn the medical community on its ear by mass marketing his work, making it widely available. He says, Essentially what Im envisioning here is that this could be on your shelf at your Walgreens, your Kmart. Lets say you suspect you have a conditionyou buy the test for that. And you can see immediately if you have it. Instead of your doctor being the doctor, youre the doctor. The teenager reports that hes already in talks with major corporations like LabCorp and QuestDiagnostics to bring his kits to store shelves as soon as possible, though how long that may actually take isnt yet known.

But if it seems like everything comes easily to the Maryland student, don't be fooled. While in the process of soliciting area labs for research space, he was rejected by 197 scientists, some of whom told him quite plainly his theory couldn't possibly work. Only one person said yes, but it turned out to be the right personDr. Anirban Maitra, a professor of pathology and oncology at Johns Hopkins University, who also became Jack's mentor.

It's easy to chalk up Jack Andraka's success to the luck that comes with being brillianthe is ridiculously smart. But there's more to him than that. His innate sense of social justice tells him that in a country as developed as ours, the fact that we have so many people dying every day of what could be a treatable disease is a wrong he intends to make right. "What motivates me is that 100 people die every day from pancreatic cancer. And so when I'm working I think those 100 people are who I'm working for today."

Is Jack Andraka an example of why we need more science in schools? Let us know what you think in the Comments.

Read more here:

Did This 15-Year-Old Kid Just Change the Course of Medicine?

CardioDx’s Leadership to Speak at the 5th Annual Personalized Medicine World Conference

PALO ALTO, Calif.--(BUSINESS WIRE)--

CardioDx, Inc. announced today that President and CEO, David Levison, and Chief Medical Officer, Mark Monane, M.D., will present at the 5th Annual Personalized Medicine World Conference (PMWC) on Tuesday, January 29, 2013 in Mountain View, CA. Mr. Levison will provide a company perspective on the reimbursement pathway for molecular diagnostic tests, and Dr. Monane will present an overview of Corus CAD, the only clinically validated gene expression test for obstructive coronary artery disease.

Corus CAD is a decision-making tool that can help primary care clinicians and cardiologists exclude obstructive coronary artery disease (CAD) as the cause of a stable non-diabetic patient's symptoms. The test involves a routine blood draw conveniently administered in the clinicians office, and does not expose patients to radiation or imaging agent intolerance. It is the only sex-specific test for obstructive CAD, accounting for critical biological differences between men and women. Corus CAD has now been used to assess more than 35,000 U.S. patients.

We are living in one of the most exciting times in the evolution of medicine, and 2013 promises to be a pivotal year in the clinical adoption of personalized diagnostics and treatments, said Levison. By applying genomics to healthcare decision making, a healthcare practitioner can act on information that provides real-time insights on a patients disease state and prescribe the most suitable course of treatment for that patient. Unlike genetic tests which can only try to predict a persons predisposition to specific diseases, the Corus CAD gene expression test can help primary care clinicians and cardiologists exclude the diagnosis of obstructive CAD early in the diagnostic pathway, thus helping clinicians make better patient management decisions that may lead to improved quality of patient care, while lowering overall costs to the healthcare system.

Mr. Levison will present A Company Perspective on Reimbursement, discussing the opportunities and challenges in obtaining reimbursement coverage for molecular diagnostics and personalized medicine. Levison will share knowledge gained from the CardioDx experience in obtaining Medicare coverage for more than 40 million Medicare enrollees in the U.S. for the Corus CAD test. He will also review successful clinical strategies for working with payers to achieve positive coverage decisions and examine the role of Palmetto GBAs MolDx Program in clarifying the process and requirements for coverage. The presentation will take place on January 29 at 11:00 AM PT as part of Track 1, Session 4: Economics of PM.

Dr. Monane will provide an overview of CardioDx and Corus CAD, the only clinically validated cardiovascular genomic test designed to help clinicians safely, accurately, and conveniently determine from a blood sample whether their patients symptoms are due to blockages in the heart arteries. Corus CAD is a gene expression test that integrates the expression levels of 23 genes involved in the development of and/or response to atherosclerosis into a single score, which has been proven to accurately identify patients without obstructive CAD. Gene expression tests enable clinicians to act on genomic information and provide patients a more tailored management plan. The presentation is titled, Noninvasive Testing for Coronary Artery Disease and will take place on January 29 at 9:30 AM PT as part of Track 2, Session 7: Diagnostics and Healthcare Treatment.

About Corus CAD

Corus CAD is the first and only clinically validated blood-based test for the assessment of obstructive coronary artery disease. The test involves a routine blood draw conveniently administered in the clinicians office and does not expose patients to risks of radiation or imaging agent intolerance. It is the first sex-specific test for obstructive coronary artery disease, accounting for critical biological differences between men and women. The test has been honored as a winner of The Wall Street Journal's prestigious Technology Innovation Awards and one of TIME's Top Ten Medical Breakthroughs and is a finalist for the 2012 Edison Awards. Findings from the PREDICT validation study of the Corus CAD gene expression test were published in 2010 in the Annals of Internal Medicine, the journal of the American College of Physicians.

The Corus CAD test measures the RNA levels of 23 genes from a whole blood sample. Because these RNA levels are increased or decreased when obstructive coronary artery disease is present, the Corus CAD score indicates the likelihood that an individual patient does not have obstructive coronary artery disease.

Corus CAD is commercially available through an innovative patient sample kit that includes everything needed for blood collection and express delivery to the companys CLIA-certified Palo Alto, Calif. laboratory. Test results are delivered promptly to the clinicians office. Corus CAD is currently available in the United States.

More here:

CardioDx’s Leadership to Speak at the 5th Annual Personalized Medicine World Conference

Ryan Rail Jam 2013 – Liberty Mountain Resort – Video


Ryan Rail Jam 2013 - Liberty Mountain Resort
The 8th Ryan Lichtenberg Memorial Rail Jam was held at Liberty Mountain Resort on January 27, 2013. The terrain park comp honors the memory of Ryan Lichtenberg and strives to promote helmet safety! Check out the video and next time you #39;re riding make sure to strap on a helmet for Ryan. Safe Riding For Ryan! http://www.libertymountainresort.com Also find us on Facebook and Twitter http://www.facebook.com twitter.com

By: LibertyMountainPA

Continued here:

Ryan Rail Jam 2013 - Liberty Mountain Resort - Video

My First Entry for Liberty Jane Clothing New Years Design Contest 2013! – Video


My First Entry for Liberty Jane Clothing New Years Design Contest 2013!
Here is my first entry! Thank you for watching and I hope you like the outfit 🙂 If you have any questions, just comment and I will reply ASAP and if you need to make any changes, go ahead 🙂

By: agdolls1011

See original here:

My First Entry for Liberty Jane Clothing New Years Design Contest 2013! - Video

Police charge man over Liberty Bell threat

By CNN Staff

updated 3:33 PM EST, Sun January 27, 2013

The cracked Liberty Bell, in Philadelphia, is seen as a symbol of America's quest for independence.

STORY HIGHLIGHTS

(CNN) -- An Arizona man accused of threatening to blow up Philadelphia's Liberty Bell was charged Sunday, police said.

Carlos Balsas, 41, of Tempe, Arizona, is charged with terroristic threats, bomb threats and several other offenses, police spokeswoman Christine O'Brien said. Prosecutors approved the charges and will take up the case Monday, she said.

It was unclear whether Balsas had retained an attorney.

Authorities say Balsas claimed to have explosives as he entered the historic site. Later, two black backpacks were found in front of the Liberty Wheels wheelchair and scooter rental shop in downtown Philadelphia.

Police said a bomb squad was called in and secured the scene but found that the bags did not contain explosives.

"I have no idea why" the man allegedly did this, O'Brien said.

See more here:

Police charge man over Liberty Bell threat

Further Metallurgical Testing on New Liberty Ore Confirms Gold Recovery and Reduces Reagent Consumption and CIL …

TSX: AUE AIM : AUE

TORONTO , Jan. 28, 2013 /CNW/ - Aureus Mining Inc. ("Aureus" or the "Company") is pleased to announce that the metallurgical optimization test work programme undertaken as part of the on-going New Liberty Project ("New Liberty" or the "Project") optimization phase confirms a substantial improvement on the results in the original Technical Report published in October 2012 . Key highlights include:

Metallurgical test work has shown encouraging results with improved leach kinetics indicating that the recovery of 93% modelled in the Technical Report is achievable at a reduced carbon in leach ("CIL") residence time of 24 hours (previously 48 hours), with significantly lower reagent consumption. These improvements will impact positively on both the capital and operating costs. Overall plant recovery will be defined when an economic trade-off has been completed to quantify the recovery benefit associated with the inclusion of a regrind mill.

The extensive optimization test work was completed on a 240kg representative bulk composite sample and six variability composite samples from the New Liberty deposit and has produced the following key results:

Commenting on the metallurgical test results, David Reading stated:

"These metallurgical results, which indicate significantly lower operating costs due to factors which include a shorter CIL residence time and lower consumption of reagents, further demonstrate the strong economics of New Liberty. This is the first set of results for what is an on-going optimization programme, the full results of which will be available towards the end of the first quarter of this year. We are confident the results of this programme will further enhance the returns for all stakeholders on what will be Liberia's first commercial gold mine."

Introduction Subsequent to the feasibility study the Company initiated optimization phase for the Project. The objective of the optimization phase test work was to finalize the flowsheet and optimize reagent consumption while achieving an overall test work recovery of 93%.

Metallurgical Testwork Programme A metallurgical test work programme has been completed as part of the optimization phase. The test work programme was undertaken by the Australian, Perth based, ALS Laboratories ('ALS').

In October 2012 , 800kg of pre-crushed (12.7mm) core sample material was delivered to ALS's mineral progressing facility for metallurgical characterization test work. This material was the product material from comminution test work conducted on core samples at JKtech in September 2012 . The sample material received from JKtech was composited to produce a 240kg bulk master composite sample for test work aimed at finalizing the flowsheet and optimizing reagent consumption. This bulk sample was comprised of pre-crushed core samples from the western and central portions of the deposit at various depths. The master composite had a gold grade of 4.23g/t. In addition to the test work conducted on the master composite sample, further variability test work was conducted using the optimized flowsheet and reagent consumptions. Six (6) variability samples were prepared from the pre-crushed core samples as received from JKtech and four (4) additional drill core samples which were delivered to ALS in December 2012 . The four additional drill core sample mass totalled 136kg. The variability samples had a measured gold grade ranging from 4.26 g/t - 10.44g/t.

The scope of work of the test work programme included:

Follow this link:

Further Metallurgical Testing on New Liberty Ore Confirms Gold Recovery and Reduces Reagent Consumption and CIL ...

Model Liberty Ross, film director Rupert Sanders divorcing

British filmmaker Rupert Sanders (L) hasn't seen his wife, actress Liberty Ross (R), since news of his affair with Kristen Stewart broke last month, People.com said. Both Sanders and Stewart issued public apologies for hurting their respective partners after photos were published July 24 showing the director and his "Snow White and the Huntsman" leading lady embracing and kissing. Sanders and Ross have been married seven years and are the parents of two children. The couple are pictured attending a screening of the film on May 29. UPI/Jim Ruymen/file photo

License photo

Published: Jan. 28, 2013 at 12:02 AM

LOS ANGELES, Jan. 27 (UPI) -- British model Liberty Ross has filed for divorce from film director Rupert Sanders, her husband of 10 years, legal documents filed in Los Angeles show.

Ross, 34, filed the divorce papers Friday, months after her husband, 41, was photographed in a steamy embrace with actress Kristen Stewart, the 22-year-old star of his movie, "Snow White and the Huntsman."

Ross appeared in the big-screen fairy tale as the mother of a younger version of Stewart's Snow White character.

Both Sanders and Stewart apologized publicly for their affair and insisted it was over.

"This was a long time coming," UsMagazine.com quoted a source close to Ross and Sanders as saying about Ross' divorce filing.

The insider said Sanders "did want to try to repair the relationship and didn't want a divorce." However, a second person with knowledge of the situation told the magazine Ross was too upset to forgive and forget.

The couple have two children together -- Skyla, 7, and Tennyson, 5.

View post:

Model Liberty Ross, film director Rupert Sanders divorcing